Johnson & Johnson announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label extensiona, evaluating the long-term efficacy and safety of ...

During a live event, Richard F. Riedel, MD, discussed key efficacy and safety outcomes from the phase 3 DeFi trial in ...

Taking probiotics may reduce negative mood, according to a new clinical trial. The results build on evidence showing the ...

University of Calgary researchers investigate transcranial magnetic stimulation (TMS) to treat aphasia caused by stroke.

Switzerland: A new research, published in the Journal of Oral and Maxillofacial Surgery revealed that low-level laser therapy ...

VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on ...

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”) announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) ...

Researchers have found in a new research that Double Antibiotic Paste (DAP) exhibited significantly better outcomes than ...

A new study published in the Journal of Clinical Oncology suggests that a common over-the-counter drug may significantly ...

Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on dosing, data on a ketamine ...